[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoadjuvant-chemoradiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoadjuvant-chemoradiotherapy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100649158","hyperpolarized-13c-mri-and-radiomics-in-rectal-cancer-100649158",false,"NCT07730541","Hyperpolarized 13C-MRI and Radiomics in Rectal Cancer","Integrated Precision Imaging for Rectal Cancer Patients Undergoing Total Neoadjuvant Therapy: Hyperpolarized 13C-MRI, Metabolomics, and Radiomics","DNP_RECA","Inclusion Criteria:\n\n1. Patients with biopsy proved rectal adenocarcinoma.\n2. Patents will undergo neoadjuvant chemoradiation therapy (nCRT).\n3. Patients more than 20-year-old.\n\nExclusion Criteria:\n\n2\\. Contraindication to MRI study (e.g., claustrophobia or non-removable devices or implants that are incompatible with MRI). 3. Intercurrent illness that will affect the compliance of the patient during the MRI study (e.g., active infection, symptomatic congestive heart failure, uncontrollable angina, arrhythmia, psychiatric disorders, dyspnea, or diarrhea). 4. Severe hepatic dysfunction (alkaline phosphatase\u002Faspartate aminotransferase\u002Falanine aminotransferase \\>20 × upper limit of normal \\[ULN\\] or bilirubin \\> 10 × ULN). 5. Severe renal impairment (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2).",true,"ALL","20 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","This study is testing new imaging and analysis methods to improve how doctors predict treatment response in rectal cancer patients receiving chemoradiotherapy. Current MRI scans sometimes miss complete tumor response, which can lead to unnecessary surgery. To address this, researchers will use a special MRI technique called hyperpolarized carbon-13 MRI, along with blood and tissue analysis (metabolomics) and advanced image feature analysis (radiomics). These tools can track how cancer cells use energy and how metabolism changes during treatment.\n\nThe study will follow 30 rectal cancer patients at Chang Gung Memorial Hospital over 3 years. Patients will undergo standard MRI, colonoscopy, and advanced metabolic imaging before and after treatment. Results will compare patients whose tumors completely respond to therapy with those who do not. The goal is to see if metabolic changes detected by hyperpolarized MRI and metabolomics can predict treatment outcomes earlier and more accurately. This may help doctors avoid unnecessary surgery and provide more personalized care for rectal cancer patients.",[26],"Neoadjuvant Chemoradiotherapy",[26,28,29,30],"Rectal Cancer","Hyperpolarized 13C-MRI","Pyruvate","RECRUITING","2026-07-23",{"date":34,"type":35},"2026-07-28","ACTUAL",{"date":37,"type":35},"2026-06-01",{"date":39,"type":22},"2028-07-30",{"name":41,"class":42},"Chang Gung Memorial Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100425114","theragnostic-utilities-for-neoplastic-diseases-of-the-rectum-by-mri-guided-radiotherapy-100425114","NCT04815694","THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy","THUNDER2","Inclusion Criteria:\n\n* Histological proven adenocarcinoma of the rectum;\n* cT2-4, or cN0-2 (also extramesorectal nodes), or mesorectal fascia involvement for tumor (MRF+) or extramural venous invasion (EMVI+);\n* cM0;\n* No prior radiotherapy in pelvic region;\n* Tumour located between 0 and 15 cm above the anal verge;\n* Not mesorectal fascia involvement for tumor;\n* No extramesorectal nodes involvement;\n* No extramural venous invasion (EMVI);\n* No rectal mucinous adenocarcinoma histology;\n* No contra-indications for MRI;\n* ECOG 0-1;\n* Age over 18 years;\n* Adequate hematological function: granulocyte count \\> 1500\u002Fmicrol, Hemoglobin level \\> 10 g\u002Fdl, Platelet count \\> 100000\u002Fmicrol, ALT\u002FAST: 7-45 UI\u002FL;\n* No other malignancies in the previous history (except skin and initial cervical cancer);\n* Absence of important comorbidities: severe cardiac or coagulative disease, moderate or severe restrictive\u002Fobstructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment;\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;\n* Absence of pregnancy or lactating female patients;\n* Written informed consent.\n\nExclusion Criteria:\n\n* Distant metastases (cM1);\n* Prior radiotherapy in the pelvic region;\n* Tumour located lower than 0 cm or higher than 15 cm above the anal verge;\n* Rectal mucinous adenocarcinoma histology;\n* Contra-indications for Magnetic Resonance Imaging (MRI);\n* Eastern Cooperative Oncology Group (ECOG) performance status score \\>= 2;\n* Age under 18 years;\n* Inadequate hematological function (Granulocyte count \\\u003C= 1500\u002Fmicrol, Hemoglobin level \\\u003C= 10 g\u002Fdl, Platelet count \\\u003C= 100000\u002Fmicrol, ALT\u002FAST outside 7-45 UI\u002FL);\n* History of other malignancies (except skin cancer and initial cervical cancer);\n* Presence of severe comorbidities (severe cardiac or coagulative disease, moderate or severe restrictive\u002Fobstructive lung deficit, severe cognitive impairment, moderate\u002Fsevere renal or hepatic impairment);\n* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;\n* Pregnant or lactating female patients.","18 Years",{"count":53,"type":22},179,"INTERVENTIONAL",[56],"NA","Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free survival, and overall survival.\n\nThe aim of this clinical trial is to investigate the impact of radiotherapy dose escalation in rectal cancer by identifying poor responders during treatment using the Early Tumor Regression Index (ERI). Patients are treated using magnetic resonance-guided radiotherapy (MRgRT). ERI is calculated at fraction 10. Patients with an ERI value below 13.1 continue the standard treatment schedule, whereas patients with an ERI value above 13.1 undergo adaptive replanning with dose escalation up to 60.1 Gy to the residual tumor volume.\n\nConcomitant chemotherapy consists of fluoropyrimidine-based treatment, with oxaliplatin permitted in patients at high risk of recurrence. In selected high-risk patients, consolidation chemotherapy with three cycles of FOLFOX may be administered during the interval before surgery.\n\nFollowing protocol amendments, the study was expanded to include a total planned enrollment of 179 patients. Additional blood samples for circulating tumor DNA (ctDNA) analysis and stool samples for gut microbiome profiling are collected at predefined time points. These longitudinal multi-omics data are integrated with magnetic resonance imaging-based delta-radiomics features to develop composite biomarker models for prediction of treatment response.\n\nThe primary outcome measures are complete response, defined as ypT0N0 after Total Mesorectal Excision (TME), ypT0 ycN0 after Local Excision (LE), or ycT0N0 in patients managed with Watch and Wait, and the prospective validation of the magnetic resonance-guided radiotherapy delta-radiomics predictive model.",[26,59,60],"Locally Advanced Rectal Cancer","Pathological Complete Response",[62,63],"MRI guided radiotherapy","Early Regression Index- ERI","2026-07-08",{"date":66,"type":35},"2026-07-10",{"date":68,"type":35},"2021-03-17",{"date":70,"type":22},"2031-10",{"name":72,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100572700","oral-immunonutrition-therapy-to-reduce-acute-toxicity-after-neoadjuvant-chemoradiotherapy-pancreatic-cancer-patients-100572700","NCT06736678","Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients","Efficacy of Oral Immunonutrition Therapy in Reducing Acute Toxicity After Neoadjuvant Chemoradiotherapy Among Pancreatic Cancer Patients: a Prospective, Single-arm Clinical Trial","Inclusion Criteria:\n\n* 1\\. Pathologically confirmed pancreatic ductal epithelial malignant tumors;\n* 2\\. Resectable pancreatic cancer treated with neoadjuvant chemoradiotherapy, or nonresectable locally advanced pancreatic cancer treated with neoadjuvant or radical chemoradiotherapy;\n* 3.Nutritional Risk Screening 2002 (NRS2002) ≥3 and Patient-Generated Subjective Global Assessment (PG-SGA) performance status B;\n* 4\\. Age 18 years and older;\n* 5\\. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* 6\\. Expected survival time more than 3 months;\n* 7\\. History of antineoplastic therapy;\n\nExclusion Criteria:\n\n* 1\\. Known allergy or intolerance to any component of investigational Oral Immunonutrition;\n* 2\\. History of Oral Immunonutrition use within one month prior to enrollment;\n* 3\\. Tumor compresses the major duodenal papilla, and \u002For appeared jaundice, acute pancreatitis;\n* 4\\. Patients with contraindications for antineoplastic therapy, such as coronary heart disease, cerebral infarction, cerebral hemorrhage or other serious diseases;\n* 5\\. Liver, kidney and blood coagulation function failure;\n* 6\\. Patients with hemopathy;\n* 7\\. Patients with active infections;\n* 8\\. Patients with other primary tumor;\n* 9\\. Patients with other medical diseases that seriously affected nutritional status;\n* 10.Subjects deemed by the investigator have other factors that may be ineligible for enrollment;",{"count":81,"type":22},98,[56],"A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.",[85,26,86],"Pancreatic Cancer","Immunonutrition","2024-12-12",{"date":89,"type":35},"2024-12-17",{"date":91,"type":35},"2024-08-26",{"date":93,"type":22},"2025-09-30",{"name":95,"class":42},"Sun Yat-sen University",2]